MX2021002113A - Uso de gaboxadol en el tratamiento de trastornos del tracto gastrointestinal y asma. - Google Patents
Uso de gaboxadol en el tratamiento de trastornos del tracto gastrointestinal y asma.Info
- Publication number
- MX2021002113A MX2021002113A MX2021002113A MX2021002113A MX2021002113A MX 2021002113 A MX2021002113 A MX 2021002113A MX 2021002113 A MX2021002113 A MX 2021002113A MX 2021002113 A MX2021002113 A MX 2021002113A MX 2021002113 A MX2021002113 A MX 2021002113A
- Authority
- MX
- Mexico
- Prior art keywords
- asthma
- gaboxadol
- treatment
- gastrointestinal tract
- tract disorders
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title abstract 3
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title abstract 2
- 229950004346 gaboxadol Drugs 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 210000001035 gastrointestinal tract Anatomy 0.000 title 1
- 208000015943 Coeliac disease Diseases 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 2
- 208000011231 Crohn disease Diseases 0.000 abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 208000008275 microscopic colitis Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721013P | 2018-08-22 | 2018-08-22 | |
| PCT/US2019/047673 WO2020041574A1 (en) | 2018-08-22 | 2019-08-22 | Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002113A true MX2021002113A (es) | 2021-06-23 |
Family
ID=69591079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002113A MX2021002113A (es) | 2018-08-22 | 2019-08-22 | Uso de gaboxadol en el tratamiento de trastornos del tracto gastrointestinal y asma. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210177805A1 (enExample) |
| EP (1) | EP3823619A4 (enExample) |
| JP (1) | JP2021535106A (enExample) |
| KR (1) | KR20210049855A (enExample) |
| CN (1) | CN112888437A (enExample) |
| AU (1) | AU2019326539A1 (enExample) |
| CA (1) | CA3110218A1 (enExample) |
| IL (1) | IL280859A (enExample) |
| MX (1) | MX2021002113A (enExample) |
| WO (1) | WO2020041574A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| CN115551514A (zh) * | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸系统病症的药物的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0974351A3 (en) * | 1998-04-24 | 2000-12-13 | Jouveinal | Medicament for preventing and treating gastrointestinal damage |
| AU4307800A (en) * | 1999-04-30 | 2000-11-17 | Merab Lomia | New indication for use of antiepileptic agents and medicines |
| EP1863808A1 (en) * | 2005-03-18 | 2007-12-12 | Transform Pharmaceuticals, Inc. | Gaboxadol forms, compositions thereof, and related methods |
| US20070203216A1 (en) * | 2006-02-14 | 2007-08-30 | Bjarke Ebert | Method of treating inflammatory diseases |
| CN108024997A (zh) * | 2015-07-17 | 2018-05-11 | 奥维德医疗公司 | 用加波沙朵治疗发育障碍的方法 |
-
2019
- 2019-08-22 CN CN201980069028.1A patent/CN112888437A/zh active Pending
- 2019-08-22 EP EP19852671.7A patent/EP3823619A4/en not_active Withdrawn
- 2019-08-22 MX MX2021002113A patent/MX2021002113A/es unknown
- 2019-08-22 CA CA3110218A patent/CA3110218A1/en active Pending
- 2019-08-22 AU AU2019326539A patent/AU2019326539A1/en not_active Abandoned
- 2019-08-22 US US17/270,377 patent/US20210177805A1/en not_active Abandoned
- 2019-08-22 JP JP2021509210A patent/JP2021535106A/ja not_active Withdrawn
- 2019-08-22 KR KR1020217008438A patent/KR20210049855A/ko not_active Withdrawn
- 2019-08-22 WO PCT/US2019/047673 patent/WO2020041574A1/en not_active Ceased
-
2021
- 2021-02-14 IL IL280859A patent/IL280859A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3110218A1 (en) | 2020-02-27 |
| EP3823619A4 (en) | 2021-11-17 |
| IL280859A (en) | 2021-04-29 |
| WO2020041574A1 (en) | 2020-02-27 |
| EP3823619A1 (en) | 2021-05-26 |
| JP2021535106A (ja) | 2021-12-16 |
| US20210177805A1 (en) | 2021-06-17 |
| AU2019326539A1 (en) | 2021-03-11 |
| KR20210049855A (ko) | 2021-05-06 |
| CN112888437A (zh) | 2021-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002321A (es) | Nuevos metodos. | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| EP4487908A3 (en) | Methods of treating crohn's disease and ulcerative colitis | |
| WO2017087608A8 (en) | Modulators of ror-gamma | |
| MY166228A (en) | Compositions comprising mixtures of semifluorinated alkanes | |
| JP2016163571A5 (enExample) | ||
| PH12021551455A1 (en) | Jak1 pathway inhibitors for the treatment of gastrointestinal disease | |
| MX2025003477A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| MX378890B (es) | Bifidobacterium longum ncimb 41715 para usarse en el tratamiento de obesidad y trastornos metabólicos asociados. | |
| MX2022008842A (es) | Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial. | |
| MX2019009190A (es) | Uso de gaboxadol en el tratamiento de tinnitus. | |
| MX2020010302A (es) | Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares. | |
| EA201790563A8 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| ZA201805358B (en) | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| JOP20190209A1 (ar) | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان | |
| WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
| WO2018128722A8 (en) | Use of gut microbiota in the diagnosis and therapeutics of parkinson's disease | |
| WO2016025671A3 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| WO2018085516A3 (en) | Non-mesenchymal human lung stem cells and methods of their use for treating respiratory diseases | |
| MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| IL280859A (en) | Use of gboxdol for the treatment of gastrointestinal disorders and asthma | |
| MY203365A (en) | Montelukast for the treatment of erosive hand osteoarthritis | |
| MX2025002392A (es) | Formulaciones de dantroleno y metodos de uso de dichas formulaciones | |
| MX2021003302A (es) | Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez. |